ACP |
acyl carrier protein |
AMP |
antimicrobial peptide |
BCS |
Biopharmaceutical Classification System |
CC |
combinatorial chemistry |
CDC |
Centers for Disease Control and Prevention |
CNS |
central nervous system |
ECDC |
European Center for Disease Prevention and Control |
EMA |
European Medicines Agency |
EPI: |
efflux pump inhibitor |
ETH |
ethionamide |
FDA |
Food and Drug Administration |
HTS |
high-throughput screening |
IDSA |
Infectious Diseases Society of America |
IM |
inner membrane |
IMI |
Innovative Medicines Initiative |
INH |
isoniazid |
IV |
intravenous therapy |
MDR |
multidrug resistant |
MRSA |
methicillin-resistant Staphylococcus aureus
|
NAD |
nicotinamide adenine dinucleotide |
ND4BB |
New Drugs 4 Bad Bugs |
OM |
outer membrane |
PO |
oral therapy |
POA |
pyrazinoic acid |
PYR |
pyrazinamide |
PDR |
pandrug resistant |
RDD |
rational drug design |
ROS |
reactive oxygen species |
R&D |
research and development |
RO5 |
Lipinsky’s Rule of Five |
TB |
tuberculosis |
XDR |
extensively drug resistant |
WHO |
World Health Organization |